Asthma Biologics Denied by Insurance? How to Appeal

Biologic medications have transformed the treatment of severe, uncontrolled asthma. For patients with eosinophilic asthma or allergic asthma who continue to experience frequent exacerbations despite maximal inhaler therapy, biologics like mepolizumab (Nucala), benralizumab (Fasenra), dupilumab (Dupixent), tezepelumab (Tezspire), and omalizumab (Xolair) can dramatically reduce exacerbation rates, oral corticosteroid use, and hospitalizations. Despite FDA approval and endorsement by the Global Initiative for Asthma (GINA) at Step 5, these medications are among the most frequently denied specialty drugs. The right documentation and a guideline-driven appeal give you a strong path to reversal.

Why Insurers Deny Asthma Biologics

Step therapy requirements beyond GINA standards. The insurer requires documented failure of high-dose inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and sometimes oral corticosteroids (OCS) before approving a biologic — steps that GINA Step 5 guidelines already address. The problem arises when insurers impose additional steps or documentation requirements that exceed GINA recommendations.

Biomarker thresholds not documented. Each biologic has specific eligibility criteria — blood eosinophil counts, serum IgE levels, allergen sensitivity documentation. Mepolizumab (Nucala) requires blood eosinophils at or above 150 cells/µL at initiation; benralizumab (Fasenra) requires at or above 300 cells/µL; omalizumab (Xolair) requires elevated IgE and perennial allergen sensitivity. Denials occur when labs are slightly below the plan's threshold or documentation is incomplete.

Severity classification dispute. The insurer characterizes your asthma as moderate rather than severe — preventing access to GINA Step 5 therapy — despite clinical evidence of frequent exacerbations, systemic corticosteroid dependence, or documented poor symptom control scores.

Formulary preference over clinical preference. The insurer has a preferred biologic on its formulary — often based on rebate negotiations rather than clinical merit — and denies the specific agent your pulmonologist or allergist prescribed, even when there is a documented clinical reason to prefer it.

Authorization renewal denied for stable patients. After initially approving a biologic, the insurer refuses renewal — claiming insufficient demonstrated response — even when your physician documents reduced exacerbation frequency, reduced OCS use, and improved quality of life as evidence of clinical benefit.

How to Appeal an Asthma Biologic Denial

Step 1: Request the Clinical Policy Bulletin and Compare to GINA Step 5

Obtain the insurer's complete clinical policy bulletin (CPB) for biologic asthma therapy. Compare the stated biomarker thresholds, step therapy sequence, and severity criteria to GINA 2024 Step 5 recommendations. GINA Step 5 criteria include: ACQ-5 score at or above 1.5 or ACT score below 20 (poor symptom control); two or more moderate exacerbations per year requiring systemic corticosteroids; one or more severe exacerbations requiring emergency visit or hospitalization; and daily or near-daily symptoms despite high-dose ICS/LABA. Any insurer criterion more restrictive than GINA Step 5 is a specific basis for appeal.

irometry-documentation">Step 2: Compile Complete Biomarker and Spirometry Documentation

Gather all relevant laboratory and pulmonary function data: spirometry results (FEV1 pre- and post-bronchodilator, FVC, FEV1/FVC ratio); complete blood count with differential showing eosinophil count (cells/µL); fractional exhaled nitric oxide (FeNO) measurement in parts per billion; serum total IgE level and allergen-specific IgE results (for omalizumab); ACQ-5 or ACT questionnaire scores with dates; and a complete prior asthma medication history with doses and dates of initiation and discontinuation.

Step 3: Document Every Exacerbation Over the Prior 12 to 24 Months

Create a detailed chronological log of all asthma exacerbations: emergency department visits with dates and treatment records; hospitalizations with admission and discharge summaries; urgent care visits; courses of oral or parenteral corticosteroids with dates, drug name, and doses; and school or work absences attributable to asthma. This documented exacerbation burden is the most concrete clinical evidence of severe uncontrolled asthma and is the core evidence GINA Step 5 criteria require.

Step 4: Obtain a Comprehensive Letter From Your Pulmonologist or Allergist

Your specialist should write a letter that: explicitly states GINA Step 5 criteria are met with specific values (ACT/ACQ score, eosinophil count, exacerbation count); identifies the specific biologic requested and explains why it is appropriate for your asthma phenotype (eosinophilic, allergic, or type-2 low for tezepelumab); documents all prior controller therapy with dates and reasons for failure or inadequate response; cites the GINA 2024 guidelines by name; and explains the clinical consequences of continued denial, including ongoing severe exacerbations, steroid toxicity from OCS dependence, and hospitalization risk.

Step 5: File the Internal Appeal With a Step Therapy Override Request

Submit your appeal with the physician's letter, all biomarker values with lab reports, the exacerbation log, GINA guideline pages, and an explicit challenge to any insurer criterion more restrictive than GINA Step 5. Request a peer-to-peer review between your specialist and the insurer's medical director. Under ACA Section 2719 (42 U.S.C. § 300gg-19), you have the right to a full internal appeal with clinical review by a specialist in the relevant field.

Step 6: Invoke State Step Therapy Override Laws and Request External Independent Review: Complete Guide" class="auto-link">External Review

Many states — including New York, Texas, Illinois, Colorado, and others — have enacted step therapy override laws requiring insurers to grant exceptions when the required step therapy drug is clinically inappropriate, previously failed, or contraindicated. File a complaint with your state insurance commissioner citing your state's specific step therapy statute if applicable. After internal appeal exhaustion, request external independent review under ACA Section 2719, ensuring the reviewer is a board-certified pulmonologist or allergist with expertise in biologic therapy.

What to Include in Your Appeal

• Denial letter and the insurer's clinical policy bulletin for biologic asthma therapy
• Spirometry results (FEV1, FVC), eosinophil count, FeNO, IgE levels (as applicable to the specific biologic)
• ACQ-5 or ACT symptom control scores with dates
• Exacerbation log with ER visits, hospitalizations, and OCS courses over the prior 12 to 24 months
• Pulmonologist or allergist letter of medical necessity citing GINA 2024 Step 5 criteria with all biomarker values

Fight Back With ClaimBack

Asthma biologic denials are winnable — but they require precise documentation of biomarker values, exacerbation history, and step therapy failures that directly address GINA Step 5 criteria. ClaimBack generates a professional appeal letter in 3 minutes, citing GINA guidelines, the FDA-approved indication for your specific biologic, and the applicable step therapy override protections in your state.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal